Luteolin and its glycoside have been reported to regulate NF-κB, MAPK, and JAK/STAT pathways, and to modify the effects induced by pro-inflammatory cytokines such as TLRs, TNF, IL-1TNF, IL-1, and IL-6 [123]. Luteolin controls glucose metabolism, cell growth, and the apoptosis process, which are often not regulated in malignant cells. Hence, luteolin is an anti-cancer compound [124] with potential treatment for diabetes [125]. The gene discussed is SOAT1; the disease is diabetes mellitus.